Sagimet Biosciences SGMT Institutional Ownership

Updated Oct 11, 2026

Sagimet Biosciences Inc. (NASDAQ:SGMT) counted 122 institutional investors among its 13F-reported shareholders for the quarter ended June 30, 2026.

• These investors held 82.57% of Sagimet Biosciences' outstanding shares at the end of Q2 2026, up from 40.98% in Q1 2026.
• Total shares held in SGMT rose 282.05% from Q1 2026; the number of holders rose 87.69% from Q2 2025.
• Of the 122 holders of SGMT in Q2 2026, 95 added to their positions, 10 reduced their stakes and 17 left their positions unchanged.
• Combined, institutional investors held 51.01Mn shares of SGMT as of Q2 2026, up 37.66Mn from the prior quarter and up 39.64Mn from a year earlier.
• BlackRock, Inc. held the largest position in SGMT at 6.58Mn shares as of June 30, 2026, or 10.64% of shares outstanding.
• Among existing holders, the largest additions to Sagimet Biosciences in Q2 2026 came from BlackRock, Inc. (+5.78Mn shares), Federated Hermes, Inc. (+2.09Mn shares), Woodline Partners LP (+2Mn shares), State Street Corp (+1.87Mn shares) and Affinity Asset Advisors, LLC (+1.63Mn shares).
• Among holders that kept a stake in Sagimet Biosciences, the biggest sellers in Q2 2026 were D. E. Shaw & Co., Inc. (-389.39K shares), Renaissance Technologies LLC (-278.54K shares), Hudson Bay Capital Management LP (-253.44K shares), Susquehanna International Group, LLP (-113.65K shares) and Bridgeway Capital Management, LLC (-78.1K shares).
• Business Quant data shows the 10 biggest positions in Sagimet Biosciences as of Q2 2026 were held by BlackRock, Inc. (6.58Mn shares), Balyasny Asset Management L.P. (3.63Mn shares), Woodline Partners LP (3Mn shares), Silverarc Capital Management, LLC (2.93Mn shares), Vanguard Capital Management LLC (2.57Mn shares), BVF Inc (2.5Mn shares), Caligan Partners LP (2.5Mn shares), Affinity Asset Advisors, LLC (2.5Mn shares), Federated Hermes, Inc. (2.09Mn shares) and Great Point Partners LLC (2.03Mn shares).